S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.22 (-0.69%)
DOW   33,344.21 (-0.82%)
QQQ   353.59 (-0.18%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
LON:VENN

Venn Life Sciences (VENN) Share Forecast, Price & News

GBX 6.85
+0.45 (+7.03%)
(As of 06/27/2019)
Today's Range
6.70
7
50-Day Range
6.85
6.85
52-Week Range
1.55
7.25
Volume
1.03 million shs
Average Volume
566,253 shs
Market Capitalization
£4.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VENN stock logo

About Venn Life Sciences (LON:VENN) Stock

Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling. It also provides clinical trial services comprising clinical feasibility assessment, project management, clinical and medical monitoring, biometrics, biostatistics, data management and databases integration, ISC/IDMC, RTSM, investigator initiated studies, and resourcing and recruitment. In addition, the company offers regulatory affairs and consulting, quality assurance, and legal services, as well as drug development training and courses. The company has a strategic collaboration with Open Orphan DAC for the clinical research and regulatory consulting for companies developing products under the auspices of the various Orphan Drug frameworks. The company was founded in 2012 and is headquartered in Dublin, Ireland.

VENN Price History

VENN Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
SBW Life Sciences Co. Ltd.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
2023 Life Sciences Awards
See More Headlines
Receive VENN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Venn Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Medical Care
Sub-Industry
N/A
Sector
N/A
CIK
N/A
Fax
N/A
Employees
157
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
GBX 15.60 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.89 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Anthony Richardson (Age 55)
    CEO, Exec. Director & Company Sec.
  • Dr. Christian Bernard Milla (Age 57)
    COO & Director













VENN Stock - Frequently Asked Questions

How have VENN shares performed in 2023?

Venn Life Sciences' stock was trading at GBX 6.85 at the beginning of the year. Since then, VENN stock has increased by 0.0% and is now trading at GBX 6.85.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Venn Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Venn Life Sciences investors own include Nielsen (NLSN), Bank of Hawaii (BOH), BJ's Wholesale Club (BJ), Biogen (BIIB), Bank of America (BAC), Arrow Electronics (ARW), Art's-Way Manufacturing (ARTW), Arconic (ARNC), ADOMANI (ADOM) and Adobe (ADBE).

What is Venn Life Sciences' stock symbol?

Venn Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "VENN."

How do I buy shares of Venn Life Sciences?

Shares of VENN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Venn Life Sciences' stock price today?

One share of VENN stock can currently be purchased for approximately GBX 6.85.

How much money does Venn Life Sciences make?

Venn Life Sciences (LON:VENN) has a market capitalization of £4.89 million.

How many employees does Venn Life Sciences have?

The company employs 157 workers across the globe.

How can I contact Venn Life Sciences?

Venn Life Sciences' mailing address is 1 Berkeley Street, LONDON, W1J 8DJ, United Kingdom. The official website for the company is www.vennlifesciences.com. The company can be reached via phone at +44-28-90737900.

This page (LON:VENN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -